Global Innovative Platforms (GIPL) Cash from Operations Growth (3y) (2023 - 2026)
Powered by 
Analysis
Global Innovative Platforms (GIPL) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.57 Bn | 40.38 Bn | 779.09 Mn | 20.12% |
| 2 | Zoetis | 30.57 Bn | 28.90 Bn | 1.05 Bn | 52.97% |
| 3 | Elanco Animal Health | 11.47 Bn | 10.94 Bn | 798.00 Mn | 65.60% |
| 4 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 134.40 Mn | 5.99% |
| 5 | Immucell | 87.38 Mn | 78.52 Mn | 2.44 Mn | - |
| 6 | Zhengye Biotechnology Holding | 64.40 Mn | 57.30 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | -113.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -113.87% |
| Mar 31, 2026 | 138.86% |
| Dec 31, 2025 | -117.23% |
| Sep 30, 2025 | -106.11% |
| Jun 30, 2025 | -152.11% |
| Sep 30, 2024 | -1,425.96% |
| Jun 30, 2024 | -26.17% |
| Mar 31, 2024 | 59.83% |
| Dec 31, 2023 | -30.63% |